Ligand begins Phase ll trial of LGD-6972 to treat type 2 diabetes mellitus

US-based biopharmaceutical company Ligand Pharmaceuticals Incorporated has begun a Phase ll clinical trial of its glucagon receptor antagonist LGD-6972 to treat type 2 diabetes mellitus (T2DM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news